相关临床试验
144
23 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
21
14.6%
已完成
98
68.1%
尚未招募
2
1.4%
招募中
11
7.6%
终止
1
0.7%
Unknown
6
4.2%
撤回
5
3.5%
暂无批准数据
- Queen's University Belfast (QUB) offers MSc programmes in Pharmaceutical Analysis, including an International Industrial Placement pathway and a fully funded Higher Level Apprenticeship, to address rising demand for skilled analysts. - The courses provide hands-on training on state-of-the-art separation and characterisation techniques, including HPLC/MS, GC/MS, NMR spectroscopy, and X-ray crystallography, in a purpose-built laboratory designed with Agilent. - Professor Peter Nockemann, Course Director, notes an "exponential increase in the demand for highly-skilled analytical scientists, both in industry and academia." - Graduates have secured roles at companies including Almac, Randox, Norbrook, Pfizer, and AbbVie, reflecting strong employability outcomes in the pharmaceutical sector.
- Researchers at Queen's University Belfast have developed a dissolvable 3D-printed microneedle patch that delivers two anti-cancer drugs directly to the skin without drawing blood. - The patch delivers curcumin and 5-fluorouracil for potential use in localised skin cancer, offering more targeted delivery than repeated topical applications or injections. - A one-step 3D-printing method blends the drugs directly into the microneedles, enabling better skin penetration, higher drug loading, and a controlled two-stage release. - Because the microneedles dissolve after use, the approach may reduce needle-stick injuries and medical sharps waste while supporting future vaccine and drug delivery technologies.
- Lynette McHendry, diagnosed with aggressive inflammatory triple-negative breast cancer at age 37, has achieved eight years of remission following a decade-long battle that included brain metastases. - Access disparities in Northern Ireland meant patients were initially denied platinum-based chemotherapy and PARP inhibitors, treatments particularly relevant for BRCA1-mutated cancers. - Professor Stuart McIntosh of Queen's University Belfast highlights that earlier diagnosis, personalised treatments, and expanded treatment options are driving continued improvement in patient outcomes. - Northern Ireland's cancer trials network has made a significant and active contribution to cancer research worldwide, including pioneering national clinical trials on PARP inhibitors.
- Fusion Antibodies has successfully humanised a DR5-targeting therapeutic antibody using its proprietary CDRx® platform, with all variants showing positive results in tumour cell death assays. - UK Research & Innovation has extended the grant-funded project timeline to 31 December 2026, allowing further pre-clinical evaluation in relevant cancer models. - The company leveraged new microfluidic technology at the Future Medicines Institute to accelerate stable cell line development by approximately 50%, reducing the process to around four months. - Positive pre-clinical results are expected to support a patent application and create a licensable therapeutic asset for partnering with pharmaceutical or biotechnology companies.
- Scientists from the University of Sheffield, UCL Great Ormond Street Institute, and Queen's University Belfast are developing a stem cell therapy to provide a permanent cure for Hirschsprung disease, a rare condition affecting newborns' digestive systems. - The £2.7 million UKRI-funded project has created a method to grow missing enteric nervous system nerves from human stem cells in just six days, nearly twice as fast as existing methods. - The lab-grown cells have demonstrated effectiveness in restoring gut function in patient tissue samples and are "off-the-shelf" ready, meaning they can be frozen and transported to hospitals across the UK. - Early health economic modeling suggests this one-time cell therapy could be highly cost-effective compared to the current treatment approach of repeat surgeries and specialized care.
- Artelo Biosciences has secured a fully funded investigator-sponsored clinical trial to evaluate ART27.13, its peripherally selective synthetic cannabinoid, in glaucoma patients with first enrollment expected in Q2 2026. - The study is funded by Glaucoma UK and HSC R&D Division, targeting the $16.3 billion global glaucoma market projected to grow at 7.05% annually through 2033. - ART27.13's peripheral selectivity may overcome historical limitations of cannabinoid therapies by avoiding central nervous system side effects while potentially reducing intraocular pressure through novel mechanisms. - This capital-efficient development strategy expands ART27.13's therapeutic potential beyond its lead indication in cancer-related anorexia without requiring additional shareholder investment.
- PharmaTher Holdings Ltd. has introduced PatchPrint™, an automated tabletop microneedle patch production platform with provisional patent filing, designed for end-to-end manufacturing of personalized drug delivery patches. - The company is expanding its PharmaPatch™ microneedle transdermal system to deliver therapeutic peptides including BPC-157, GHK-Cu, TB-500, and KPV peptides in the U.S. market, targeting tissue repair and inflammation management applications. - The hydrogel-forming microneedle arrays offer significant advantages over conventional delivery methods by avoiding first-pass liver metabolism, enhancing drug absorption, and enabling precise micro-dosing with improved patient adherence. - PharmaTher is aligning with FDA regulatory requirements for future submissions, with plans to initiate preclinical toxicology studies and first-in-human trials pending IND authorization.
- Panakeia's PANProfiler Colorectal (MSI/MMR) software demonstrated 93.83% agreement with standard laboratory testing in the largest real-world, multi-site validation study of AI molecular profiling to date. - The AI software successfully returned results on 86.55% of cases across 1,243 colorectal cancer patients from three UK healthcare institutions, delivering molecular biomarker analysis in minutes rather than weeks. - Published in npj Digital Medicine, the study addresses critical gaps in molecular testing access, with national audits showing substantial proportions of eligible patients experience testing delays of several weeks. - The UKCA-marked software is now deployed in UK hospitals and selected for the MHRA's AI Airlock programme, positioning it for broader healthcare system implementation.
- Niagen Bioscience has acquired a comprehensive patent portfolio covering nicotinamide riboside (NR) and its salt forms from Queen's University Belfast, consolidating critical intellectual property for NAD+ precursors. - The acquisition includes foundational composition-of-matter patents covering crystal morphologies, manufacturing methods, and commercial use of NR, providing the strongest form of IP protection available. - The company now holds sole ownership of more than 90 issued and pending patents worldwide across NR and other NAD+ precursors, enhancing strategic flexibility for pharmaceutical applications. - US Patent No. 12,252,506 is among the acquired assets, covering multiple NR salt forms including NR Malate and NR Tartrate derivatives.
- Scientists have discovered pre-methylenomycin C lactone, the first compound in a promising new class of antibiotics, through unexpected research into bacterial biosynthesis pathways. - The novel antibiotic demonstrates 100-fold greater efficacy against drug-resistant bacteria compared to the original compound, including MRSA and multidrug-resistant Enterococcus faecium. - Crucially, the compound showed no signs of inducing antibiotic resistance in bacteria over a 28-day exposure study, addressing a critical challenge in antimicrobial development. - Researchers are now collaborating to develop synthetic production methods and investigate the compound's mechanism of action for potential therapeutic applications.
